Jeffrey B. Landau - Mar 23, 2022 Form 3 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
Chief Business Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Jeffrey B Landau
Stock symbol
CTMX
Transactions as of
Mar 23, 2022
Transactions value $
$0
Form type
3
Date filed
3/28/2022, 04:12 PM
Next filing
Jul 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CTMX Common Stock 4.5K Mar 23, 2022 Fidelity Traditional IRA
holding CTMX Common Stock 3.18K Mar 23, 2022 Schwab ROTH IRA
holding CTMX Common Stock 18.6K Mar 23, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CTMX Stock Option (Right to Buy) Mar 23, 2022 Common Stock 275K $6.74 Direct F3
holding CTMX Stock Option (Right to Buy) Mar 23, 2022 Common Stock 30K $5.34 Direct F4
holding CTMX Performance Stock Units (PSUs) Mar 23, 2022 Common Stock 22.5K Direct F5
holding CTMX Stock Option (Right to Buy) Mar 23, 2022 Common Stock 97.6K $4.13 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 16,274 restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on March 15 of each year, with the first 1/4th vesting on March 15, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F2 Includes 2,367 shares under the CytomX Therapeutics Employee Stock Purchase Plan.
F3 25% of the shares subject to the option vest on the one-year anniversary measured from April 12, 2021 (the "Vesting Commencement Date"), and 1/48 monthly thereafter such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
F4 1/48th of the shares subject to the option vest on each monthly anniversary measured from October 24, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
F5 Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone within 1 year from grant date and 50% of the PSUs vest upon achievement of a certain performance-based milestone within 2 years from grant date.
F6 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.